Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.

Wright AJ, Fishman JA, Chung RT.

Am J Transplant. 2014 Mar;14(3):629-34. doi: 10.1111/ajt.12598. Epub 2014 Jan 24.

2.

Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.

Saab S, Ham MY, Stone MA, Holt C, Tong M.

Liver Transpl. 2009 Apr;15(4):413-20. doi: 10.1002/lt.21712.

3.

Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.

Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS Jr.

Transplantation. 2013 Apr 15;95(7):960-5. doi: 10.1097/TP.0b013e3182845f97.

PMID:
23545507
4.

Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.

Oliveira GL, Almeida AM, Silva AL, Brandão CM, Andrade EI, Cherchiglia ML, Acurcio Fde A.

Rev Saude Publica. 2013 Aug;47(4):769-78; discussion 779. doi: 10.1590/S0034-8910.2013047004529. English, Portuguese.

5.

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG.

Pharmacoeconomics. 2007;25(11):963-77.

PMID:
17960954
6.

Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.

Wu B, Li T, Chen H, Shen J.

Value Health. 2010 Aug;13(5):592-600. doi: 10.1111/j.1524-4733.2010.00733.x. Epub 2010 Apr 30.

7.

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.

Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG.

Aliment Pharmacol Ther. 2008 Jun;27(12):1240-52. doi: 10.1111/j.1365-2036.2008.03691.x. Epub 2008 Mar 27. Review. Erratum in: Aliment Pharmacol Ther.2008 Jul;28(1): 166. Bisceglie, A [corrected to Di Bisceglie, A].

8.

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.

Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y.

BMC Health Serv Res. 2014 Apr 14;14:170. doi: 10.1186/1472-6963-14-170.

9.

Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.

Lee KK, Wu DB, Chow PY, Lee VW, Li H.

J Gastroenterol Hepatol. 2012 Jul;27(7):1167-74. doi: 10.1111/j.1440-1746.2011.07047.x.

PMID:
22141402
10.

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.

Lui YY, Tsoi KK, Wong VW, Kao JH, Hou JL, Teo EK, Mohamed R, Piratvisuth T, Han KH, Mihm U, Wong GL, Chan HL.

Antivir Ther. 2010;15(2):145-55. doi: 10.3851/IMP1496.

PMID:
20386069
11.

[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].

Almeida AM, Silva AL, Brandão CM, Cherchiglia ML, Andrade EI, Araújo de Oliveira GL, Carmo RA, Acurcio Fde A.

Rev Saude Publica. 2012 Dec;46(6):942-9. Portuguese.

12.

Economic evaluation of treatments for chronic hepatitis B.

Wiens A, Lenzi L, Venson R, Pedroso ML, Correr CJ, Pontarolo R.

Braz J Infect Dis. 2013 Jul-Aug;17(4):418-26. doi: 10.1016/j.bjid.2012.12.005. Epub 2013 Jul 10. Review.

13.

Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.

Singer GA, Zielsdorf S, Fleetwood VA, Alvey N, Cohen E, Eswaran S, Shah N, Chan EY, Hertl M, Fayek SA.

Transplant Proc. 2015 Mar;47(2):478-84. doi: 10.1016/j.transproceed.2014.11.029.

PMID:
25769595
14.

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

Arnold E, Yuan Y, Iloeje U, Cook G.

Appl Health Econ Health Policy. 2008;6(4):231-46. doi: 10.2165/00148365-200806040-00005.

PMID:
19382822
15.

Should chronic hepatitis B be treated as early as possible?

Hulstaert F, Schwierz C, Nevens F, Thiry N, Gamil M, Colle I, Van de Sande S, Horsmans Y.

Int J Technol Assess Health Care. 2013 Jan;29(1):35-41. doi: 10.1017/S0266462312000736. Epub 2013 Jan 8.

PMID:
23298548
16.

[Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].

Kim BK, Kwon SY, Lee CH, Choe WH, Choi HM, Koo HW.

Korean J Hepatol. 2009 Mar;15(1):25-41. doi: 10.3350/kjhep.2009.15.1.25. Korean.

17.
18.
19.

Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.

Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, Zhou S, Yang Y.

Hepatol Int. 2016 Nov;10(6):924-936. Epub 2016 Jun 7.

PMID:
27271357
20.

Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Dakin H, Sherman M, Fung S, Fidler C, Bentley A.

Pharmacoeconomics. 2011 Dec;29(12):1075-91. doi: 10.2165/11589260-000000000-00000.

PMID:
22077579

Supplemental Content

Support Center